Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Change in Accured Expenses (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Change in Accured Expenses for 11 consecutive years, with $1.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Accured Expenses fell 8.94% to $1.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$3.6 million, a 46.77% increase, with the full-year FY2025 number at -$3.6 million, up 46.77% from a year prior.
  • Change in Accured Expenses was $1.1 million for Q4 2025 at Cartesian Therapeutics, up from -$432000.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $3.2 million in Q2 2022 to a low of -$6.4 million in Q1 2024.
  • A 5-year average of -$490850.0 and a median of -$381000.0 in 2022 define the central range for Change in Accured Expenses.
  • Peak YoY movement for Change in Accured Expenses: surged 716.67% in 2023, then tumbled 222.78% in 2024.
  • Cartesian Therapeutics' Change in Accured Expenses stood at -$679000.0 in 2021, then surged by 332.25% to $1.6 million in 2022, then crashed by 171.21% to -$1.1 million in 2023, then soared by 203.56% to $1.2 million in 2024, then fell by 8.94% to $1.1 million in 2025.
  • Per Business Quant, the three most recent readings for RNAC's Change in Accured Expenses are $1.1 million (Q4 2025), -$432000.0 (Q3 2025), and -$2.0 million (Q2 2025).